Related references
Note: Only part of the references are listed.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C
Tanya L. Applegate et al.
ANTIVIRAL THERAPY (2015)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection
Mika Miura et al.
HEPATOLOGY RESEARCH (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hepatitis C virus NS5A inhibitors and drug resistance mutations
Shingo Nakamoto et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
Doug J. Bartels et al.
JOURNAL OF VIROLOGY (2013)
Updating benchtop sequencing performance comparison
Sebastian Juenemann et al.
NATURE BIOTECHNOLOGY (2013)
Epidemiology and natural history of HCV infection
Behzad Hajarizadeh et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region
Shuang Wu et al.
PLOS ONE (2013)
A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers
Michael A. Quail et al.
BMC GENOMICS (2012)
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
Fumitaka Suzuki et al.
JOURNAL OF CLINICAL VIROLOGY (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
New antiviral therapies for chronic hepatitis C
Tatsuo Kanda et al.
HEPATOLOGY INTERNATIONAL (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3
V. Schregel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Impact of viral eradication on mortality related to hepatitis C: A modeling approach in France
Sylvie Deuffic-Burban et al.
JOURNAL OF HEPATOLOGY (2008)
Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy
Koichi Watashi et al.
REVIEWS IN MEDICAL VIROLOGY (2007)
Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival
Y Shiratori et al.
ANNALS OF INTERNAL MEDICINE (2005)
Share Paper
